- Corporate Officers - P
- Papadopoulos Stelios
Insider Trading History of Papadopoulos Stelios
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Papadopoulos Stelios since 2015.
This trader's CIK number is 1202098.
At the time of last reporting, Papadopoulos Stelios was the Director of Exelixis, Inc.. (stock ticker symbol EXEL).
Also see all insider trading activities at Exelixis, Inc..
Note that in the past
PAPADOPOULOS STELIOS also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Exelixis, Inc. (EXEL) by Papadopoulos Stelios
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | EXEL | 0 | $0 | 136,508 | $5,974,129 | 36,508 | $735,088 |
| 2024 | EXEL | 0 | $0 | 11,437 | $240,177 | 11,686 | $228,695 |
| 2022 | EXEL | 0 | $0 | 84,515 | $1,653,113 | 0 | $0 |
| 2021 | EXEL | 0 | $0 | 20,770 | $518,979 | 120,000 | $512,399 |
| 2020 | EXEL | 0 | $0 | 45,000 | $1,162,800 | 165,791 | $939,253 |
| 2019 | EXEL | 0 | $0 | 26,250 | $557,812 | 26,250 | $114,581 |
| 2018 | EXEL | 0 | $0 | 30,000 | $693,000 | 30,000 | $294,450 |
| 2017 | EXEL | 0 | $0 | 220,000 | $6,005,986 | 10,000 | $105,300 |
Yearly summary of insider trading at Biogen Inc. (BIIB) by Papadopoulos Stelios
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2015 | BIIB | 10,000 | $3,048,780 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Regulus Therapeutics Inc. (RGLS) by Papadopoulos Stelios
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | RGLS | 420,370 | $454,549 | 0 | $0 | 0 | $0 |
| 2018 | RGLS | 616,401 | $793,817 | 0 | $0 | 0 | $0 |
| 2017 | RGLS | 1,500,000 | $1,517,900 | 0 | $0 | 0 | $0 |
| 2015 | RGLS | 0 | $0 | 0 | $0 | 50,677 | $80,728 |
Insider trading activities at 3 companies by Papadopoulos Stelios:
1. Exelixis, Inc. (EXEL)
2. Biogen Inc. (BIIB)
3. Regulus Therapeutics Inc. (RGLS)
Table 1. Insider trading of Exelixis, Inc. (EXEL) by Papadopoulos Stelios
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-11-12 | EXEL | Sale | 100,000 | 43.55 | 4,355,000 |
| 2025-05-15 | EXEL | Option Ex | 36,508 | 20.14 | 735,088 |
| 2025-05-15 | EXEL | Sale | 36,508 | 44.35 | 1,619,129 |
| 2024-05-20 | EXEL | Option Ex | 11,686 | 19.57 | 228,695 |
| 2024-05-20 | EXEL | Sale | 11,437 | 21.00 | 240,177 |
| 2022-02-22 | EXEL | Sale | 84,515 | 19.56 | 1,653,113 |
| 2021-05-11 | EXEL | Option Ex | 120,000 | 4.27 | 512,399 |
| 2021-05-11 | EXEL | Sale | 20,770 | 24.99 | 518,979 |
| 2020-05-13 | EXEL | Option Ex | 120,791 | 5.82 | 703,003 |
| 2020-05-08 | EXEL | Option Ex | 45,000 | 5.25 | 236,250 |
| 2020-05-08 | EXEL | Sale | 45,000 | 25.84 | 1,162,800 |
| 2019-02-21 | EXEL | Option Ex | 26,250 | 4.37 | 114,581 |
| 2019-02-21 | EXEL | Sale | 26,250 | 21.25 | 557,812 |
| 2018-05-07 | EXEL | Option Ex | 15,000 | 11.66 | 174,900 |
| 2018-05-07 | EXEL | Sale | 15,000 | 22.15 | 332,250 |
| 2018-03-02 | EXEL | Option Ex | 15,000 | 7.97 | 119,550 |
| 2018-03-02 | EXEL | Sale | 15,000 | 24.05 | 360,750 |
| 2017-09-22 | EXEL | Sale | 10,000 | 25.40 | 254,000 |
| 2017-09-19 | EXEL | Sale | 127,790 | 27.63 | 3,530,837 |
| 2017-09-18 | EXEL | Sale | 72,210 | 27.76 | 2,004,549 |
| 2017-03-20 | EXEL | Option Ex | 10,000 | 10.53 | 105,300 |
| 2017-03-20 | EXEL | Sale | 10,000 | 21.66 | 216,600 |
Table 2. Insider trading of Biogen Inc. (BIIB) by Papadopoulos Stelios
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2015-07-27 | BIIB | Buy | 10,000 | 304.88 | 3,048,780 |
Table 3. Insider trading of Regulus Therapeutics Inc. (RGLS) by Papadopoulos Stelios
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-05-07 | RGLS | Buy | 370,370 | 1.08 | 399,999 |
| 2018-12-28 | RGLS | Buy | 50,000 | 1.09 | 54,550 |
| 2018-12-26 | RGLS | Buy | 90,000 | .95 | 85,860 |
| 2018-12-27 | RGLS | Buy | 26,401 | 1.04 | 27,457 |
| 2018-11-15 | RGLS | Buy | 200,000 | 1.32 | 265,000 |
| 2018-11-16 | RGLS | Buy | 300,000 | 1.39 | 415,500 |
| 2017-07-25 | RGLS | Buy | 1,000,000 | .91 | 910,000 |
| 2017-03-21 | RGLS | Buy | 200,000 | 1.20 | 239,800 |
| 2017-03-22 | RGLS | Buy | 300,000 | 1.23 | 368,100 |
| 2015-08-07 | RGLS | Option Ex | 50,677 | 1.59 | 80,728 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Papadopoulos Stelios
(Director of Exelixis, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.